GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SLS BIO Co Ltd (XKRX:246250) » Definitions » Gross-Profit-to-Asset %

SLS BIO Co (XKRX:246250) Gross-Profit-to-Asset % : 12.80% (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is SLS BIO Co Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. SLS BIO Co's annualized Gross Profit for the quarter that ended in Mar. 2024 was ₩2,266 Mil. SLS BIO Co's average Total Assets over the quarter that ended in Mar. 2024 was ₩17,702 Mil. Therefore, SLS BIO Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 12.80%.


SLS BIO Co Gross-Profit-to-Asset % Historical Data

The historical data trend for SLS BIO Co's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SLS BIO Co Gross-Profit-to-Asset % Chart

SLS BIO Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only 31.86 21.22 21.12 37.83 21.03

SLS BIO Co Quarterly Data
Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross-Profit-to-Asset % Get a 7-Day Free Trial 22.32 35.48 17.59 23.53 12.80

Competitive Comparison of SLS BIO Co's Gross-Profit-to-Asset %

For the Diagnostics & Research subindustry, SLS BIO Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SLS BIO Co's Gross-Profit-to-Asset % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, SLS BIO Co's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where SLS BIO Co's Gross-Profit-to-Asset % falls into.



SLS BIO Co Gross-Profit-to-Asset % Calculation

SLS BIO Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=3111.466/( (11752.854+17837.584)/ 2 )
=3111.466/14795.219
=21.03 %

SLS BIO Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=2266.376/( (17837.584+17567.099)/ 2 )
=2266.376/17702.3415
=12.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


SLS BIO Co Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of SLS BIO Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


SLS BIO Co (XKRX:246250) Business Description

Traded in Other Exchanges
N/A
Address
Gwanggyo Central Biz Tower, 7th floor, Changryong-dong 260, Gyeonggi-do, Suwon-si, KOR, 16229
SLS BIO Co Ltd is engaged in providing drug development supporting services and pharmaceutical product QC through general tests and assays and instrumental analysis.

SLS BIO Co (XKRX:246250) Headlines

No Headlines